KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis
The hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tract, spleen, and/or liver, caused by an activating KIT mutation in the KIT gene.
United States Avapritinib Ayvakit Prithviraj Bose Midostaurin Rydapt International Working Group American Society Of Hematology Annual Meeting
Source: onclive.com